A Phase 3 interventional study of Diclofenac Sodium Topical Gel, 1% and Voltaren Topical Gel, 1% in Osteoarthritis, sponsored by Amneal Pharmaceuticals, LLC. Completed at 23 sites in India. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2021-06-16.
Sponsored by Amneal Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Osteoarthritis with a site in India — none open to participants now, none under way, none of them phase 3. Osteoarthritis · India.
Among the 23 studies in Osteoarthritis with a site in India, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 3, and was the 12th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →None of the 23 studies in Osteoarthritis with a site in India is open now. The open studies under Osteoarthritis, anywhere →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 3 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,176 is above the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 76 across the 21 interventional studies, 108 across the 2 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amneal Pharmaceuticals, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Amneal Pharmaceuticals, LLC is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Amneal Pharmaceuticals, Inc. has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Osteoarthritis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To establish the therapeutic equivalence and safety of a generic Diclofenac Sodium Topical Gel, 1% with Voltaren® Gel 1% in subjects with osteoarthritis of the knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Drug: Diclofenac Sodium Topical Gel, 1%
Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Drug: Voltaren Topical Gel, 1%
Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
Drug: Vehicle Diclofenac Sodium Topical Gel
Opaque, white gel
Opaque, white gel
Opaque, white gel
Change From Baseline to 4 Weeks in WOMAC Pain Score
Mean change from baseline to week 4 in the Western Ontario McMaster Osteoarthritis (WOMAC) pain score: 5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4
Time frame: Baseline and Week 4
| Milestone | Diclofenac Sodium Topical Gel, 1% | Voltaren Topical Gel, 1% | Vehicle Diclofenac Sodium Topical Gel |
|---|---|---|---|
| Started | 392 | 393 | 391 |
| Completed | 385 | 389 | 381 |
| Not completed | 7 | 4 | 10 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 4 |
| Withdrew: Protocol violation | 1 | 2 | 4 |
| Withdrew: Concomitant therapy | 0 | 1 | 1 |
| Withdrew: Others | 1 | 0 | 1 |
Mean change from baseline to week 4 in the Western Ontario McMaster Osteoarthritis (WOMAC) pain score: 5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4
| score on a scale | Diclofenac Sodium Topical Gel, 1% | Voltaren Topical Gel, 1% | Vehicle Diclofenac Sodium Topical Gel |
|---|---|---|---|
| Change From Baseline to 4 Weeks in WOMAC Pain Score | 2.2332 ± 0.1160 | 2.0287 ± 0.1157 | -0.6387 ± 0.1172 |
Collected over The over all time frame for any the Adverse Events is maximum 9days starting from date of appearance to date of disappearance.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diclofenac Sodium Topical Gel, 1% | 0/391 (0%) | 0/391 (0%) | 2/391 (0.5%) |
| Voltaren Topical Gel, 1% | 0/393 (0%) | 0/393 (0%) | 2/393 (0.5%) |
| Vehicle Diclofenac Sodium Topical Gel | 0/391 (0%) | 0/391 (0%) | 3/391 (0.8%) |
| Event | Diclofenac Sodium Topical Gel, 1% | Voltaren Topical Gel, 1% | Vehicle Diclofenac Sodium Topical Gel |
|---|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/391 | 0/393 | 1/391 |
| Oedema,General disorders | 1/391 | 0/393 | 0/391 |
| Nasopharyngitis CoughInfections and infestations | 0/391 | 0/393 | 1/391 |
| PyrexiaGeneral disorders | 0/391 | 1/393 | 1/391 |
| Pruritus and Rash PruriticSkin and subcutaneous tissue disorders | 1/391 | 0/393 | 0/391 |
| HeadacheNervous system disorders | 0/391 | 1/393 | 0/391 |
Baseline participants in the Safety population.
| Age, Customized(Participants) | Diclofenac Sodium Topical Gel, 1% | Voltaren Topical Gel, 1% | Vehicle Diclofenac Sodium Topical Gel | Total |
|---|---|---|---|---|
| <= 18 years | 0 | 0 | 0 | 0 |
| between 18 and 65 years | 357 | 351 | 354 | 1062 |
| >=65year | 34 | 42 | 37 | 113 |
| Sex: Female, Male(Participants) | Diclofenac Sodium Topical Gel, 1% | Voltaren Topical Gel, 1% | Vehicle Diclofenac Sodium Topical Gel | Total |
|---|---|---|---|---|
| Female | 255 | 244 | 254 | 753 |
| Male | 136 | 149 | 137 | 422 |
The record gives a start of Apr 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2021, 6 years 8 months after primary completion. A results delay was requested in Jun 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.